Fundraising Fox

CatalYm

Munich, DE · 56 employees on LinkedIn · 7 known investors

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment. Its lead antibody, visugromab, is being advanced through clinical trials in combination with anti-PD-1 therapies to overcome cancer therapy resistance.

BiotechDeep TechHealthtech

Founders & leadership

JW
Jörg WischhusenScientific Co-founder
SCScott Clarke
Scott ClarkeinChief Executive Officer
PGPeter Garcia
Peter GarciaChief Financial Officer
SRSujata Rao
Sujata RaoinChief Medical Officer
SRStefan Ries
Stefan RiesinChief Scientific Officer and Head of Munich Site
AGAndrea Goddard
Andrea GoddardinChief Technical Officer

Investors · 7

Jeito Capital✓ verifiedParis
Bioqube Ventures✓ verifiedBrussels · $108K – $6.5M
Forbion✓ verifiedNaarden
Bayern KapitalLandshut · $275K – $55M
Canaan PartnersStamford · $500K – $20M
Novartis Venture FundBasel · $5M – $25M
BioGeneration VenturesreportedNaarden

Funding

SEC filings, press & company announcements

$300M disclosed across 2 rounds · 2024

Source: company announcements and press reports — follow each round's link for the claim.

In the news

CatalYm raises $150m for cancer therapy visugromab - Drug Discovery World (DDW)ddw-online.com · Jul 2024German biotech raises $150M on its way to tackle cancer therapy resistancelabiotech.eu · Jul 2024German biotech CatalYm cashes in on early-stage cancer data with $150M series Dfiercebiotech.com · Jul 2024CatalYm Raises $150M in Series D Fundingfinsmes.com · Jul 2024Catalym raises US$150m - European Biotechnology Magazineeuropean-biotechnology.com · Jul 2024CatalYm raises EUR50 million to advance GDF-15 antibody into clinical trials for checkpoint-inhibitor refractory patientsglobenewswire.com · Nov 2020

Frequently asked questions

What does CatalYm do?
CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment. Its lead antibody, visugromab, is being advanced through clinical trials in combination with anti-PD-1 therapies to overcome cancer therapy resistance.
Who founded CatalYm?
CatalYm was founded by Jörg Wischhusen.
Who are CatalYm's investors?
CatalYm's investors include Jeito Capital, Bioqube Ventures, Forbion, Bayern Kapital, Canaan Partners, Novartis Venture Fund, BioGeneration Ventures.
How much funding has CatalYm raised?
CatalYm has disclosed $300M raised across 2 rounds.
Where is CatalYm headquartered?
CatalYm is headquartered in Munich, DE.